News | May 21, 2015

Tyrx Antibacterial Envelope Reduces Cardiac Device Infection Rates at 12 Months

Long-term Citadel/Centurion clinical trial findings and independent data presented at Heart Rhythm 2015

Medtronic, Tyrx Antibacterial Envelope, Heart Rhythm 2015, CIED infections

May 21, 2015 — Medtronic plc announced that its Tyrx Antibacterial Envelope reduces major cardiac device site infections by 80 percent up to 12 months after implantation. These data were presented at Heart Rhythm 2015, the Heart Rhythm Society’s 36th annual scientific sessions in Boston.

The Citadel/Centurion clinical trials are the first prospective, multicenter studies to evaluate the impact of the Tyrx Antibacterial Envelope on cardiac implantable electronic device (CIED) major infections and mechanical complication rates following implantation in high-risk patients. The results show a low rate of surgical site infection at 12 months (0.44 percent) in the 1,129 patients who received the envelope compared with a control group of similar patients reported in previously published literature who did not receive an envelope (2.2 percent; p=0.0023).

CIED infections are associated with substantial morbidity, mortality and cost, and are increasing in frequency. The average cost of a CIED infection in the United States is estimated at $54,926.

“Clinical studies show that the use of the Tyrx Envelope is associated with a significant reduction in implant-related cardiac device site infections,” said Charles A. Henrikson, M.D., MPH, FHRS, chief of electrophysiology at Oregon Health & Science University in Portland. “These new findings reveal that the Tyrx Envelope decreases the rate of infections that can occur within the first year after implantation. This is very good news for patients, especially given the associated mortality and costs tied to CIED infection.”

The Citadel/Centurion clinical trials enrolled 1,129 patients at 55 centers in the United States. Study participants were at high risk for infection because they were undergoing a CIED replacement procedure with either an implantable cardioverter-defibrillator (ICD) (Citadel) or a cardiac resynchronization therapy (CRT) device (Centurion). Primary endpoints were major CIED infection (involving any site other than skin or subcutaneous tissue of the incision, or endocarditis) and CIED mechanical complication over 12 months of follow-up. The frequency of CIED mechanical complications in patients implanted with the TYRX Envelope was low.

Additionally at Heart Rhythm 2015, researchers at Vanderbilt University Medical Center independently reported that the Tyrx Absorbable Antibacterial Envelope was associated with a very low incidence of CIED-related infection in a high-risk population, comparable to that seen with the original non-absorbable Tyrx Antibacterial Envelope.

“Our study is the first-of-its-kind, comparing the incidence of major cardiac device-related infection in high-risk patients who, during implantation, received either the Tyrx Absorbable Envelope or the non-absorbable envelope, with a control group of patients who did not receive a Tyrx envelope,” said Christopher R. Ellis, M.D., FHRS, FACC, principal investigator of the study and assistant professor of medicine at Vanderbilt University Medical Center. “After a minimum of three months, results showed only one reported infection in the 488 patients who received either the original or newer, absorbable Tyrx envelope, compared with 20 infections in the control group of 638 patients. Additionally, it was encouraging to find no difference in infection rates between the original Tyrx envelope and the newer, fully absorbable version.”

The Tyrx Antibacterial Envelope is a mesh envelope that holds an implantable cardiac device and is designed to stabilize the device after implantation while releasing two antimicrobial agents, minocycline and rifampin, over a minimum of seven days to help reduce surgical-site infections.

The Tyrx Absorbable Antibacterial Envelope is fully absorbed by the body approximately nine weeks after implantation. Both Tyrx envelopes are U.S. Food and Drug Administration (FDA)-cleared and have received CE Mark and are available in the United States and Europe.

For more information: www.medtronic.com

Related Content

A step-by-step overview of how to perform interventional CRT (I-CRT) lead placement using the coronary sinus. This image shows the Medtronic Attain Performa quadripolar lead and VivaQuad XT CRT-D system.
Feature | EP Lab | January 21, 2019 | Matthew S. McKillop, M.D., FACC, FHRS, and Seth J. Worley, M.D.
Interventional...
An implanted ICD showing its three venous leads. These multiple CRT leads can cause issues when they need to be replaced and are abandoned with new leads put over them in the SVC, which may require lead extraction.

An implanted ICD showing its three leads in the venous system. 

Feature | EP Lab | January 13, 2019 | Dave Fornell, Editor
To extract or abandon broken or infected implantable, venous...
Videos | EP Lab | January 03, 2019
This is a quick video tour of one of the dedicated...
HHS and NASA Team Up to Explore Health on Earth and in Outer Space

Image courtesy of NASA

News | EP Lab | December 14, 2018
The Department of Health and Human Services (HHS) recently entered into an interagency agreement with the National...
Technology Improvements Driving Electrophysiology Market Growth

Navik 3D Cardiac Mapping System image courtesy of APN Health.

News | EP Lab | December 10, 2018
December 10, 2018 — Electrophysiology, whil
Vagal Maneuvers With Supraventricular Tachycardia

Image courtesy of ACLS Certification Institute

Feature | EP Lab | December 05, 2018
Supraventricular tachycardia (SVT) is a common heart abnormality that presents as a fast heart rate. SVT is a generic...
Societies Publish New Guidance for Treatment of Slow, Irregular Heartbeats
News | EP Lab | November 09, 2018
The American College of Cardiology (ACC), the American Heart Association (AHA) and the Heart Rhythm Society (HRS)...
A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Overlay Init